(Q37841138)

24 August 2017

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials (English)

1 reference

24 August 2017

0 references

Peter F Thall

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

24 August 2017

1 reference

24 August 2017

25

1 reference

24 August 2017

2

1 reference

24 August 2017

227-244

1 reference

maintained by WikiProject

24 August 2017

WikiProject Mathematics

0 references

cites work

Monitoring late-onset toxicities in phase I trials using predicted risks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Sequential design and analysis of dose finding studies in patients with life threatening disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Parametric non-mixture cure models for schedule finding of therapeutic agents

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Determining the effective sample size of a parametric prior

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Determining a maximum-tolerated schedule of a cytotoxic agent.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Dose-finding based on efficacy-toxicity trade-offs

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Dose‐Finding with Two Agents in Phase I Oncology Trials

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Accrual strategies for phase I trials with delayed patient outcome.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Some practical improvements in the continual reassessment method for phase I studies.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3035990

Patient-specific dose finding based on bivariate outcomes and covariates

1 September 2018

1 reference

12 December 2020

Bayesian Optimal Designs for Phase I Clinical Trials

1 reference

12 December 2020

Dose-finding designs for HIV studies

1 reference

12 December 2020

Sequential designs for phase I clinical trials with late-onset toxicities

1 reference

12 December 2020

Simultaneously optimizing dose and schedule of a new cytotoxic agent

1 reference

12 December 2020

Patient specific dosing in a cancer phase I clinical trial

1 reference

12 December 2020

A new dose-finding design for bivariate outcomes

1 reference

12 December 2020

Identifiers

DOI

10.1214/09-STS315

1 reference

24 August 2017

0 references

1 reference

24 August 2017

PubMed publication ID

21318084

1 reference